None listed
Conditions
Interventions
Intervention1: Gremin Capsule: Gremin is a herbal formula which exert anti inflammatory and antioxidant effect in addition to improving stamina and endurance.
IP will be taken daily for 09 days. GreM
Sponsors
Zeus Hygia Lifesciences Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: Healthy subjects, moderately active (regular aerobic exercise for at least 4 hours per week), non-smoking volunteers with no known musculoskeletal pathology. Subjects with a maximal oxygen consumption (VO2max) of at least 35 ml/kg, as assessed by the maximal treadmill exercise test Subject who is identified as healthy as per clinical judgement of principal investigator Subjects willing to comply to study procedure and sign written informed consent
Exclusion criteria
Exclusion criteria: Treatment with anti-inflammatory/analgesic/antioxidant drugs in the previous month History of abnormal liver or renal function tests, laboratory findings suggestive of an active inflammatory or infectious process and presence of any known disease in last 3 months. Current alcoholism or drug abuse Allergies to one of the component substances in the trial medication (active medication) Participation in another clinical trial less than 6 months previously. Subjects with open wounds Subjects with injury involving skeletal system or deep soft tissue injury in last 3 months Subjects on steroids or ergogenic users since past 3 months Subjects with uncontrolled systemic disease since past 3 months. Subject with neurological disorders since past 3 months Any active chronic health condition that in the opinion of the investigator does not justify the subjectâ??s inclusion for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Recovery from muscle damage due to sports injury 2. Increased EnduranceTimepoint: baseline to end of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Occurrence of any AE or SAE during the study. 2. Occurrence of any clinically significant abnormality as per the Principal Investigator in the following safety marker test: Heart Rate Abbreviated POMS questionnaire Respiratory Rate Timepoint: Visits 2, Visit 3 and Visit 4 and Visit 5. | — |
Countries
India
Contacts
Public ContactShankaranarayanan J
ZeusHygia LifeSciences Pvt Ltd
Outcome results
None listed